Beta Bionics (BBNX) vs Avita Medical (RCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avita Medical (RCEL) has outperformed Beta Bionics (BBNX) over the past year, gaining 312.1% versus a loss of 57.5%. Beta Bionics is the larger company by market cap ($726.3 million vs $495.0 million), about 1.5 times the size. Avita Medical converts more of its revenue into profit, with a net margin of -67.8% versus -73.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBNX | RCEL |
|---|---|---|
| Share price | $13.36 | $15.62 |
| Market cap | $726.34M | $494.96M |
| 1-day change | +0.30% | -2.31% |
| YTD return | -56.15% | +352.75% |
| 1-year return | -57.48% | +312.14% |
| 5-year return | — | +10.78% |
| EPS (TTM) | $-1.83 | $-1.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $100.25M | $71.61M |
| Revenue growth (YoY) | +53.94% | +11.45% |
| Net income (latest FY) | $-73.20M | $-48.59M |
| Gross margin | 55.40% | 82.13% |
| Operating margin | -71.50% | -59.40% |
| Net margin | -73.02% | -67.85% |
| 52-week high | $32.71 | $18.43 |
| 52-week low | $8.80 | $3.22 |
| Distance from 52-week high | -59.16% | -15.25% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +87.87% | +32.46% |
| Average volume | 1.21M | 417.02K |
| Shares outstanding | 54.37M | 31.69M |
| Employees | 420 | 226 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCEL has outperformed BBNX by 369.6 percentage points over the past year.
- Avita Medical is more profitable, keeping -67.8 cents of every revenue dollar as net income versus -73.0 cents for Beta Bionics.
- Beta Bionics grew revenue faster in its latest fiscal year (+53.94% vs +11.45%).
About Beta Bionics
BBNX stock →Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Health Care · Medical/Dental Instruments · 420 employees
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Health Care · Medical/Dental Instruments · 226 employees
BBNX vs RCEL FAQ
Which is bigger, Beta Bionics or Avita Medical?
Beta Bionics (BBNX) is larger, with a market capitalization of $726.34M compared with $494.96M for Avita Medical (RCEL).
Which stock has performed better over the past year, BBNX or RCEL?
RCEL returned +312.14% over the past 12 months, compared with -57.48% for BBNX (price return, excluding dividends). Past performance does not predict future results.
Are Beta Bionics and Avita Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.